1
项与 Anti-CD19, Anti-CD20 CAR T Cells(Universitätsspital Basel) 相关的临床试验 / Not yet recruiting临床1期IIT A Phase I Trial of Bispecific Anti-CD19, Anti-CD20 CAR T Cells for B Cell Malignancies
This study is to provide locally produced, bispecific CD19 CD20 CAR T cells to patients with B-cell lymphoma/leukemia who have no access to commercial CAR T cells or who have relapsed thereafter. The primary objective is to assess the safety of bispecific anti-CD19, anti- CD20 CAR T cell-therapies after lymphodepleting chemotherapy in patients with B cell malignancies with exhausted standard treatment options.
100 项与 Anti-CD19, Anti-CD20 CAR T Cells(Universitätsspital Basel) 相关的临床结果
100 项与 Anti-CD19, Anti-CD20 CAR T Cells(Universitätsspital Basel) 相关的转化医学
100 项与 Anti-CD19, Anti-CD20 CAR T Cells(Universitätsspital Basel) 相关的专利(医药)
100 项与 Anti-CD19, Anti-CD20 CAR T Cells(Universitätsspital Basel) 相关的药物交易